Live feed06:15:00·1411dPRReleasevia QuantisnowGuardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung CancerByQuantisnow·Wall Street's wire, on your screen.BPMC· Blueprint Medicines CorporationGH· Guardant Health Inc.Health Care
